Molecular Templates Inc (NASDAQ:MTEM) Director David Hirsch bought 365,000 shares of the stock in a transaction dated Friday, September 21st. The stock was bought at an average price of $5.50 per share, with a total value of $2,007,500.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Shares of Molecular Templates stock opened at $5.34 on Friday. Molecular Templates Inc has a 12-month low of $4.00 and a 12-month high of $13.25. The company has a quick ratio of 3.33, a current ratio of 3.33 and a debt-to-equity ratio of 0.05. The firm has a market capitalization of $141.01 million, a PE ratio of -2.54 and a beta of 3.00.

Molecular Templates (NASDAQ:MTEM) last issued its earnings results on Thursday, August 9th. The biotechnology company reported $0.36 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.61. Molecular Templates had a negative net margin of 509.53% and a negative return on equity of 22.67%. The business had revenue of $1.37 million during the quarter. research analysts expect that Molecular Templates Inc will post -1.57 earnings per share for the current year.

Several research analysts have recently issued reports on the stock. ValuEngine cut shares of Molecular Templates from a “hold” rating to a “sell” rating in a report on Friday, July 6th. Zacks Investment Research upgraded shares of Molecular Templates from a “sell” rating to a “hold” rating in a report on Thursday, June 7th.

Several institutional investors have recently modified their holdings of the company. Northern Trust Corp boosted its stake in Molecular Templates by 36.7% during the 1st quarter. Northern Trust Corp now owns 22,152 shares of the biotechnology company’s stock worth $177,000 after purchasing an additional 5,948 shares during the period. JPMorgan Chase & Co. boosted its stake in Molecular Templates by 41.4% during the 1st quarter. JPMorgan Chase & Co. now owns 50,020 shares of the biotechnology company’s stock worth $400,000 after purchasing an additional 14,635 shares during the period. Dimensional Fund Advisors LP acquired a new stake in Molecular Templates during the 1st quarter worth $213,000. Caxton Corp boosted its stake in Molecular Templates by 2.5% during the 1st quarter. Caxton Corp now owns 1,038,787 shares of the biotechnology company’s stock worth $8,310,000 after purchasing an additional 25,000 shares during the period. Finally, Millennium Management LLC boosted its stake in Molecular Templates by 309.2% during the 1st quarter. Millennium Management LLC now owns 294,876 shares of the biotechnology company’s stock worth $2,359,000 after purchasing an additional 222,817 shares during the period. Institutional investors and hedge funds own 21.16% of the company’s stock.

Molecular Templates Company Profile

Molecular Templates, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other diseases. The company primarily develops a pipeline of engineered toxin bodies. Its lead drug candidate is MT-3724 that is in a Phase I clinical trial for the treatment of relapsed/refractory non-Hodgkin's lymphoma and B-cell lymphoma.

Recommended Story: Momentum Indicator: Relative Strength Index

Receive News & Ratings for Molecular Templates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Templates and related companies with MarketBeat.com's FREE daily email newsletter.